At Investor Conferences


Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x100px
Organisation › Details

QLi5 Therapeutics GmbH

QLi5 was founded in 2019 as a joint venture of Qurient Co. Ltd, Korea, Max Planck Society (MPG), Germany, Lead Discovery Center (LDC), Germany, Nobel laureate Prof. Robert Huber, emeritus director of the Max Planck Institute for Biochemistry, Germany. The company has established a proprietary platform for the development of proteasome inhibitors with high selectivity and unique, non-covalent binding properties. Using the proceeds of a EUR 10 million series A financing in 2022, the company is advancing its pipeline and preparing clinical trials in various indications including cancer, inflammation and autoimmune diseases. The key role of the proteasome is the elimination of misfolded, damaged or expired proteins. The principle of proteasome inhibition was discovered in many years of basic research by the Max Planck Society. The extremely complex multi-subunit protein 3D-structure of the constitutive and immunoproteasome was resolved by Prof. Huber’s lab. This solid structural understanding enabled the development of novel chemical series of proteasome inhibitors with a wide range of selectivity. *


Period Start 2020-01-16 established (s-off)
Products Industry proteasome inhibitor
  Industry 2 drug development
Region Region Dortmund
  Country Germany
  Street 15 Otto-Hahn-Str.
  City 44227 Dortmund
    Address record changed: 2022-09-27
Basic data Employees n. a.
    * Document for »About Section«: QLi5 Therapeutics GmbH. (9/7/22). "Press Release: QLi5 Therapeutics Attracts EUR 10 Million in Series A Financing". Dortmund.
Record changed: 2023-12-30


Picture [iito] [LSE] Business Portal 650x200px

More documents for QLi5 Therapeutics GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x300px

» top